EBV-associated lymphoadenopathy in a child

H.B. Mateiko; U.A. Hlushko; T.V. Nesterova; L.V. Antoniuk; N.B.  Horbal

doi:10.26641/2307-0404.2024.4.319403

Authors

H.B. Mateiko Ivano-Frankivsk National Medical University,Halytska str.,2,Ivano-Frankivsk,76018, Ukraine https://orcid.org/0000-0003-4512-4552
U.A. Hlushko Ivano-Frankivsk National Medical University, Halytska str., 2, Ivano-Frankivsk, 76018, Ukraine https://orcid.org/0000-0003-4044-766X
T.V. Nesterova Ivano-Frankivsk National Medical University, Halytska str., 2, Ivano-Frankivsk, 76018, Ukraine https://orcid.org/0009-0007-0982-1090
L.V. Antoniuk Ivano-Frankivsk National Medical University, Halytska str., 2, Ivano-Frankivsk, 76018, Ukraine https://orcid.org/0009-0006-0561-4732
N.B. Horbal Ivano-Frankivsk National Medical University, Halytska str., 2, Ivano-Frankivsk, 76018, Ukraine https://orcid.org/0000-0003-0198-6126

DOI:

https://doi.org/10.26641/2307-0404.2024.4.319403

Keywords:

Epstein-Barr virus infection, oncogenic potential, lymphoproliferative disorder, CD30-cells, lymphadenopathy, children

Abstract

Lymphadenopathy is observed in 55% of children under the age of 10 years and the most often it has a bacterial or viral etiology, but it also can manifest as lymphoproliferative diseases or lymphomas. Lymphoproliferative diseases are characterized by uncontrolled growth of lymphocytes with the development of monoclonal lymphocytosis, lymphadenopathy and bone marrow infiltration. Since the Epstein-Barr virus (EBV) has oncogenic potential, it is essential for doctors to be vigilant about generalized persistent lymphadenopathy on the background of chronic persistent Epstein-Barr infection. The purpose of the article is to increase the awareness of doctors of various specialties about the risk of developing EBV-associated lymphoproliferative diseases in children with generalized persistent lymphadenopathy using the example of a clinical case discussion. The article describes a clinical case of a 14-year-old patient with persistent lymphadenopathy on the background of chronic Epstein-Barr infection. Immunohistochemical study of the lymph node biopsy revealed reactive hyperplasia with expressed immune blast transformation, the presence of CD30-positive cells while excluding Hodgkin lymphoma. It is recommended to involve a multidisciplinary team to prescribe appropriate antiviral therapy, regularly monitor the clinical course, dynamics of laboratory and immunological indicators. The result of the study is the recommendation to repeat biopsy in the absence of positive dynamics in patients with persistent Epstein-Barr infection and lymphadenopathy.

References

Urbas OV, Vovk ZV, Holodnykh OA, Alekseieva UI, Ivanenko AL. A clinical case of manifestation of primary immunodeficiency diagnosed before as Burkitt’s lymphoma. Modern Pediatrics. 2023;4(132):104-10. doi: https://doi.org/10.15574/SP.2023.132.104

Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neo¬plasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-53. doi: https://doi.org/10.1182/blood.2022015851

Riaz IB, Faridi W, Patnaik MM, Abraham RS. (2019). A Systematic Review on Predisposition to Lym-phoid (B and T cell) Neoplasias in Patients With Primary Immuno¬deficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity). Front Immunol. 2019 Apr 16;10:777. doi: https://doi.org/10.3389/fimmu.2019.00777

Forbes LR, Eckstein OS, Gulati N, Peckham-Gregory EC, Ozuah NW, Lubega J, et al. Genetic errors of immunity distinguish pediatric nonmalignant lymphopro-liferative disorders. J Allergy Clin Immunol. 2022 Feb;149(2):758-66. doi: https://doi.org/10.1016/j.jaci.2021.07.015

LeBoeuf NR, McDermott S, Harris NL. Case 5-2015 – A 69-Year-Old Woman with Recurrent Skin Le-sions after Treatment for Lymphoma. N Engl J Med. 2015 Feb 12;372:650-9. doi: https://doi.org/10.1056/NEJMcpc1314241

Chen C, Gu YD, Geskin LJ. A Review of Primary Cutaneous CD30+ Lymphoproliferative Disorders. Hematol Oncol Clin North Am. 2019 Feb;33(1):121-34. doi: https://doi.org/10.1016/j.hoc.2018.08.003

Cui D, Zhang Y, Chen L, Du H, Zheng B, Huang M, et al. CD30 plays a role in T-dependent immune response and T cell proliferation. FASEB J. 2024 Jan;38(1):e23365. doi: https://doi.org/10.1096/fj.202301747RR

Weniger MA, Tiacci E, Schneider S, Arnolds J, Rüschenbaum S, Duppach J, et al. Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells. J Clin Invest. 2018;128(7):2996-3007. doi: https://doi.org/10.1172/JCI95993

Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, et al. The spectrum of CD30+ T cell lymphoproliferative disorders in the skin. Chin Clin Oncol. 2019;8(1):3. doi: https://doi.org/10.21037/cco.2019.01.04

Shi JH, Sun SC. Tumor Necrosis Factor Receptor-Associated Factor Regulation of Nuclear Factor κB and Mitogen-Activated Protein Kinase Pathways. Front Immunol. 2018 Aug 9;9:1849. doi: https://doi.org/10.3389/fimmu.2018.01849

Vrzalikova K, Pugh M, Mundo L, Murray P. The contribution of ebv to the pathogenesis of classical hodgkin lymphoma. Ann Lymphoma. 2021;5:30: doi: https://doi.org/10.21037/aol-21-8

Andersen O, Ernberg I, Hedström AK. Treatment options for Epstain-Barr viruses related disorder of the Central nervous system. Infection and Drug Resistance. 2023;16:4599-620. doi: https://doi.org/10.2147/IDR.S375624

Classic Hodgkin lymphoma. Ottawa Atlas of Pathology [Internet]. [cited 2024 Mar 15]. Available from: https://www.pathologyatlas.ca/galleries/hematolymphoid/classic-hodgkin-lymphoma/#foobox-1/17/classic-hodgkins-lymphoma-lymphocyte-rich-high-HRS-cells-mumified-cell.jpg

Reactive lymphadenopathy. Ottawa Atlas of Pathology [Internet]. [cited 2024 Mar 15]. Available from: https://www.pathologyatlas.ca/galleries/hematolymphoid/reactive-lymphadenopathy/#foobox-1/1/reactive-lymph-node-low.jpg